Huntington National Bank’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$36.3K Hold
756
﹤0.01% 1450
2025
Q4
$29.2K Hold
756
﹤0.01% 1446
2025
Q3
$26.7K Hold
756
﹤0.01% 1498
2025
Q2
$27.2K Buy
756
+144
+24% +$4.77K ﹤0.01% 1464
2025
Q1
$19.1K Buy
612
+72
+13% +$2.28K ﹤0.01% 1535
2024
Q4
$13.8K Buy
540
+378
+233% +$10K ﹤0.01% 1654
2024
Q3
$4.58K Buy
162
+10
+7% +$277 ﹤0.01% 2022
2024
Q2
$4.01K Sell
152
-96
-39% -$2.66K ﹤0.01% 1969
2024
Q1
$7.53K Buy
248
+73
+42% +$2.15K ﹤0.01% 1782
2023
Q4
$4.92K Sell
175
-86
-33% -$2.36K ﹤0.01% 1897
2023
Q3
$7.08K Sell
261
-142
-35% -$4.22K ﹤0.01% 1690
2023
Q2
$12.4K Sell
403
-33
-8% -$1.12K ﹤0.01% 1504
2023
Q1
$15.7K Buy
436
+175
+67% +$6.49K ﹤0.01% 1411
2022
Q4
$10.3K Sell
261
-120
-31% -$5.01K ﹤0.01% 1482
2022
Q3
$15K Sell
381
-644
-63% -$27.5K ﹤0.01% 1406
2022
Q2
$43K Hold
1,025
﹤0.01% 1051
2022
Q1
$40K Hold
1,025
﹤0.01% 1134
2021
Q4
$41K Buy
+1,025
New +$39.8K ﹤0.01% 1139

Other funds holding RPRX

Huntington National Bank's RPRX Position: Q1 2026 in Review

Huntington National Bank held its Royalty Pharma (RPRX) position steady in Q1 2026 at 756 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Huntington National Bank first reported a position in RPRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $43K in Q2 2022. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Huntington National Bank held 756 shares of Royalty Pharma worth $36.3K as of Q1 2026.
  • Huntington National Bank left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1450 holding.
  • Huntington National Bank first reported a position in Royalty Pharma in Q4 2021 and has held it in 18 quarters since.
  • Huntington National Bank's Royalty Pharma position peaked at $43K in Q2 2022.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.